| | Business Summary | | Xechem
International,
Inc.
is
a
holding
company
that
owns
all
of
the
capital
stock
of
Xechem,
Inc,
a
development
stage
biopharmaceutical
company
currently
engaged
in
the
research,
development,
and
limited
production
of
niche
generic
and
proprietary
drugs
from
natural
sources.
The
Company
is
engaged
primarily
in
applying
its
proprietary
extraction,
isolation
and
purification
technology
to
the
production
and
manufacture
of
paclitaxel,
an
anticancer
compound
used
for
the
treatment
of
ovarian,
breast,
small
cell
lung
cancers
and
AIDS
related
Kaposi
sarcomas. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Xechem
International
is
a
development
stage
bio-pharmaceutical
company
currently
engaged
in
research,
development
and
the
limited
production
of
niche
generic
and
proprietary
drugs
from
natural
sources.
For
the
six
months
ended
6/30/01,
revenues
totaled
$154
thousand,
up
from
$11
thousand.
Net
loss
increased
14%
to
$894
thousand.
Revenues
reflect
an
increase
in
consulting
fees
earned.
Higher
loss
reflects
costs
related
to
the
issuance
of
stock
and
options
for
services. | | More
from
Market Guide: Significant
Developments |
| | | Ramesh
C. Pandey,
Chmn./Pres./CEO. | More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/z/zkem.ob.gif)